In adults with uncontrolled allergic asthma, a 36-week treatment with quilizumab, an anti-M1-prime monoclonal antibody that targets IgE-switched and IgE memory B cells, did not result in a clinically significant impact on exacerbation rate, lung function, or quality of life. Here, IGHE is linked to allergic asthma.